Did you know a huge opportunity awaits you in molecular point-of-care flu testing? In this brief, 20-minute podcast, Repertoire’s Scott Adams and representatives from Henry Schein and Sekisui Diagnostics discuss molecular testing and its impact on patient outcomes, the many advantages for practices, how easy it is to sell molecular tests – and why you shouldn’t be afraid to bring it to your accounts.